Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Sep 17, 2019
Date Accepted: Feb 21, 2020

The final, peer-reviewed published version of this preprint can be found here:

Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study

Helmberger T, Arnold D, Bilbao JI, de Jong N, Maleux G, Nordlund A, Peynircioglu B, Sangro B, Sharma RA, Walk A

Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study

JMIR Res Protoc 2020;9(4):e16296

DOI: 10.2196/16296

PMID: 32319960

PMCID: 7203613

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Prospective Multicentre Observational Study on Radioembolization with 90Y Resin Microspheres: The CIRT (CIRSE Registry for SIR-Spheres Therapy) Study Protocol

  • Thomas Helmberger; 
  • Dirk Arnold; 
  • José Ignacio Bilbao; 
  • Niels de Jong; 
  • Geert Maleux; 
  • Anders Nordlund; 
  • Bora Peynircioglu; 
  • Bruno Sangro; 
  • Ricky A Sharma; 
  • Agnes Walk

ABSTRACT

Background:

Radioembolization, also known as trans-arterial radio-embolization (TARE) or Selective Internal Radiation Therapy (SIRT) with Yttrium-90 (90Y) resin microspheres is a well-studied treatment modality for patients with primary and secondary liver tumours and is used in clinical practice. Large-scale prospective observational data on the application of this treatment in the real-life clinical setting is lacking.

Objective:

The main objective is to collect data on the clinical application of radioembolization to improve the understanding of the impact of this treatment modality in its true clinical setting.

Methods:

Eligible patients are 18 years of age or older, treated with radioembolization for primary and secondary liver tumours as part of routine practice and have signed informed consent. Data is collected at baseline, right after treatment, and at every 3-month follow-up until 24 months or study exit. The primary objective of the CIRSE Registry for SIR-Spheres Therapy (CIRT) is to observe the clinical application of radioembolization and the impact of the treatment in clinical practice. Secondary objectives include safety, effectiveness in terms of overall survival (OS), progression-free survival (PFS), liver-specific PFS, imaging response and change in quality of life (QoL).

Results:

Between January 2015 and December 2017, 1050 patients were included in the study. The 24-month follow-up period will end in December 2019. The first results will be expected in the third quarter of 2020.

Conclusions:

The CIRT is the largest observational study on radioembolization to date and will provide a valuable understanding to the clinical application of this treatment modality and its real-life outcomes. Clinical Trial: CIRSE Registry for SIR-Spheres Therapy (CIRT) NCT02305459 https://clinicaltrials.gov/ct2/show/NCT02305459


 Citation

Please cite as:

Helmberger T, Arnold D, Bilbao JI, de Jong N, Maleux G, Nordlund A, Peynircioglu B, Sangro B, Sharma RA, Walk A

Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study

JMIR Res Protoc 2020;9(4):e16296

DOI: 10.2196/16296

PMID: 32319960

PMCID: 7203613

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.